Rationalisation of Polypharmacy by the Geriatric Consultation Team (RASP-GCT)

June 13, 2014 updated by: Universitaire Ziekenhuizen KU Leuven

Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study

Polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the RASP (Rationalisation of drugs on admission by an adjusted STOPP*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments.

(* = Screening Tool of Older Persons' potentially inappropriate Prescriptions)

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events .

The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgium, 3000
        • University Hospitals Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

75 years and older (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Admitted to a non-geriatric ward
  • 75 years or older
  • Dutch speaking
  • Consultation by the GCT

Exclusion Criteria:

  • End-of-life
  • No drugs on admission

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: GCT
In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
Active Comparator: GCT-RASP
Medication review, based on but not limited to the RASP list
Other: Medication review, based on but not limited to the RASP list

Systematic approach:

  1. Medication reconciliation
  2. Applying the RASP list
  3. Expert review (not based on the RASP list)
  4. Multidisciplinary discussion
Other Names:
  • RASP
  • RASP list
  • Systematic medication review

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of medication-related recommendations by the geriatric consultation team.
Time Frame: The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of potentially inappropriate drugs at discharge, as identified by the RASP list.
Time Frame: The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
Number of drugs at discharge, relative to the drugs on admission.
Time Frame: The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.
Acceptance rate of the GCT interventions by the treating physician.
Time Frame: Up to 72 hours after the GCT had given its recommendations.
Up to 72 hours after the GCT had given its recommendations.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universitaire Ziekenhuizen KU Leuven

Investigators

  • Principal Investigator: Lorenz R Van der Linden, PharmD, Universitaire Ziekenhuizen KU Leuven
  • Principal Investigator: Johan Flamaing, MD, PhD, Universitaire Ziekenhuizen KU Leuven
  • Principal Investigator: Jos Tournoy, MD, PhD, Universitaire Ziekenhuizen KU Leuven

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

February 1, 2014

Study Completion (Actual)

February 1, 2014

Study Registration Dates

First Submitted

May 26, 2014

First Submitted That Met QC Criteria

June 13, 2014

First Posted (Estimate)

June 17, 2014

Study Record Updates

Last Update Posted (Estimate)

June 17, 2014

Last Update Submitted That Met QC Criteria

June 13, 2014

Last Verified

May 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S-54896

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iatrogenic Disease

Clinical Trials on Medication review, based on but not limited to the RASP list

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe